Isolation and molecular characterization of a human T-cell lymphotropic virus type 2 (HTLV-2), subtype B, from a healthy Pygmy living in a remote area of Cameroon : an ancient origin for HTLV-2 in Africa by Gessain, A. et al.
yogogijc"; ) A  
Proc. Natl. Acad. Sci. USA 
Medical Sciences 
voi. 92, pp. 4041-4045, April 1995 . 
Isolation and molecular characterization of a human T-cell 
lymphotropic virus type II (HTLV-II), subtype B, from 
a healthy Pygmy living in a remote area of Cameroon: 
An ancient origin for HTLV-II in Africa 
ANTOINE GESSAIN", PHILIPPE MAUCLhREt, ALAIN FROMENTS, MIRNA BIGLIONE", JEAN YVES LE HESRAN§, 
FREDJ TEKAIA~, JACQUES MILLANT, AND GUY DE THÉ*I~ 
*Unité d'Epiddmiologie des Virus Oncogènes and %Service d'Informatique Scientifique, Institut Pasteur, 28, rue du Dr. Rom, 75724 Paris Cedex 15, Francc; 
tCentre Pasteur du Cameroun, BP 1274, Yaounde, Cameroon; $Museum National d'Histoire Naturelle, 91800 Brunoy, France; and §Organisation de 
Coordination pour la lutte contre les Enddmies en Afrique Centrale, Yaoundé, Cameroon 
Conimuriicated by E. D. Kilbourne, New York Medical College, Valhalla, W, December lu, 1994 
ABSTRACT We report characterization of a human T-cell 
lymphotropic virus type II (HTLV-II) isolated from an inter- 
leukin 2-dependent CD8 T-cell line derived from peripheral 
blood mononuclear cells of a healthy, HTLV-II-seropositive 
female Bakola Pygmy, aged 59, living in a remote equatorial 
forest area in south Cameroon. This HTLV-II isolate, desig- 
nated PYGCAM-1, reacted in an indirect immunofluorescence 
assay with HTLV-II and HTLV-I polyclonal antibodies antl 
with an HTLV-1/11 gp46 monoclonal antibody but not with 
HTLV-I gag p19 or p24 monoclonal antibodies. The cell line 
produced HTLV-1/11 p24 core antigen and retroviral parti- 
cles. The entire env gene (1462 bp) and most of the long 
terminal repeat (715 bp) of the PYGCAM-1 provirus were 
amplified by the polymerase chain reaction using HTLV-Il- 
specific primers. Comparison with the long terminal repeat 
and envelope sequences of prototype HTLV-II strains indi- 
cated that PYGCAM-1 belongs to the subtype B group, as it 
has only 0.5-2% nucleotide divergence from HTLV-II B 
strains. The finding of antibodies to HTLV-II in sera taken 
from the father of the woman in 1984 and from three unrelated 
members of the same population strongly suggests that PYG- 
CAM-1 is a genuine HTLV-II that has been present in this 
isolated population for a long time. The low genetic divergence 
of this African isolate from American isolates raises questions 
about the genetic variability over time and the origin and 
dissemination of HTLV-II, hitherto considered to be predom- 
inantly a New World virus. 
The origin and the routes of the worldwide dissemination of 
primate T-cell lymphotropic viruses (PTLVs), which include 
human and simian T retroviruses [HTLV-I (l), HTLV-II (2), 
STLV-I (3), and STLV-II (4)] and the recently isolated 
PTLV-L (5) ,  PTLV-PP1664 (6), and STLVpp (7), are under 
active investigation. Epidemiological and phylogenetic analy- 
ses indicate that HTLV-I and STLV-I have been present in the 
Old World (Africa and Asia) for several millenia (8-11), 
whereas HTLV-II, which is highly endemic in certain native 
Amerindian tribes (12-17), has been considered to be a New 
World virus, brought froin Asia into the Americas some 
10,000-40,000 years ago during the migration of HTLV-II- 
infected populations that occurred over the Bering land bridge 
Recent serological and molecular evidence of sporadic cases 
of HTLV-II infection in western (18, 19) and central Africa 
(20-26), however, raises the possibility that HTLV-II or a 
related retrovirus has also been present in Africa for a long 
time. This hypothesis was first suggested after the detection of 
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(12-17). 
HTLV-II-like serological markers (not verified by sequencing) 
in Pygmies in remote areas of Zaire (22, 24) and Cameroon 
(29,  who are considered to belong to the oldest ethnic groups 
in central Africa, having lived in those areas for at least 20,000 
years (27, 28). 
We report here the isolation, molecular characterization, 
and phylogenetic analysis of an HTLV-II from a healthy, 
59-year-old Pygmy woman of the Bakola population, an ethnic 
group living in a remote area of the equatorial forest of south 
Cameroon in which HTLV-II-like serological markers were 
found 10 years ago in four individuals (2.5).** 
MATERIALS AND METHODS 
Population Studied. The Bakola Pygmies are an ethnic 
group of about 400 individuals, living in the area of Akok 
(Campo district) (Z"30 N, 10" E), near Kribi in the Ocean 
Department of southern Cameroon. This group, traditionally 
hunter-gatherers, is scattered throughout the forest; they now 
practice rudimentary agriculture but also exchange game for 
staple foods and manufactured goods with neighboring farm- 
ers (27,28). In February 1994,41 Bakola Pygmies (19 men and 
22 women; mean age, 39 years) were visited, given a medical 
examination, and then bled (5 ml) after informed consent had 
been obtained. They were either relatives of the four individ- 
uals found to have HTLV-II-like serological markers in 1984, 
three of whom are now dead and the fourth untraceable, or 
people living in the same area. 
Serological Tests. The sera were screened for HTLV-1/11 by 
an enzyme-linked immunosorbent assay (ELISA; Platelia 
HTLV-I new; Sanofi, Paris) and an immunofluorescence assay 
involving HTLV-I (MT2) or HTLV-II (C19) producing cell 
lines. All positive or borderline samples were tested in a 
Western blot assay (HTLV 2.3 Diagnostic Biotechnology, 
Singapore) (29). 
Cell Culture and Virus Isolation. In March 1994, hepa- 
rinized blood specimens were collected from the individuals 
identified as HTLV-I/II-seropositive in the pilot survey and 
rushed to the Centre Pasteur in Yaoundé, where peripheral 
blood mononuclear cells (PBMCs) were separated and stored 
in liquid nitrogen. The frozen cells were transported 2 weeks 
later to Paris and thawed, and 10 million cells were placed in 
a 50-ml culture flask containing 5 ml of RPMI 1640 medium 
~ 
Abbreviations: PTLV, primate T-cell lymphotropic virus; HTLV, 
human T-cell lymphotropic virus; STLV, simian T-cell lymphotropic 
virus; PBMC, periplieral blood mononuclear cell; LTR, long terminal 
repeat. 
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Table 1. Oligonucleotide primers for DNA amplification 
Target Expected 
sequence size, bp Forward primer (5' + 3') Reverse primer (5' 4 3') 
LTR 784 LTRII TTTGAGCGGCCGCGCCCAGGGCGAGTCATCGACCC SPLTRE ACTTAGAATTCTCCCGGACGAGCCCCCAA 
Pol-env-Px 1606 AGPl TTTGAGCGCGCCGTCTCTGCCCAGTGGATCCCGTGG WH2 ACTTAGAATTCCTGCAGAAGCTAGCAGGTCTA 
Pol-env-B 1575 AGP2 TTTGAGCGGCCGAAGCGAGGTGCATGCCAAGACC WH2 ACTTAGAATTCCTGCAGAAGCTAGCAGGTCTA 
Env-Px 1013 WH1 TTTGAGCGGCCCTGCAACAACTCCATTATCCT WH3 ACTTAGAATTCGAGGAGCAGCGGGAGATCTTA 
Env-Px 595 ET403 TTTGAGCGGCCGCGGCTGGGGACTAAACTGGGATCTGGGATCTTGG WH3 ACTTAGAATTCGAGGAGCAGCGGGAGATCTTA 
Primers internal to the amplified env and long terminal repeat (LTR) products were used as oligonucleotide probes. The env probe was m V - I I  
PR (5'-GTCATATTGTTTGGCCCCTGTATCCTCCGC-3') and the LTR probe was LTRII (5'-.4AACAAGGCTCTGACGATTACCCCCCT-3'). 
with 20% heat-inactivated fetal calf serum, 1% L-glutamine, 
and 1% penicillin/streptomycin. During the subsequent 3 days, 
the cells were stimulated with phytohemagglutinin at 2 mg per 
lo6 cells and then cultivated in a humidified 5% CO2 atmo- 
sphere in the same medium as described above but with the 
addition of 10% interleukin 2. Cells were also cocultivated with 
BJAB cells after 2 weeks of culture alone. 
Indirect Immunofluorescence, Immunophenotyping, and 
Antigen Detection. Indirect immunofluorescence was per- 
formed on cultured cells; either mouse monoclonal antibodies 
directed against HTLV-I p19 or p24 (Cambridge Biotech) or 
HTLV-1/11 gp46 7G5D8 (30) or human polyclonal serum from 
HTLV-I- or HTLV-II-infected individuals was used. Cyto- 
fluorographic analysis of the cultured cells was performed as 
described (31). Production of the p24 core antigen in the 
culture supernatant was detected in a capture ELISA that 
recognizes both HTLV-I and HTLV-II (Coulter). 
Polymerase Chain Reaction (PCR). The PCR was carried 
out in a DNA thermocycler (Cetus) using high molecular 
weight DNA extracted from PBMCs, before and after 1 month 
of culture. Each initial reaction mixture contained 1.5 pg of 
DNA, 0.2 mmol of dNTP mix per liter, 10 pl of a 1OX reaction 
buffer, 0.2 mmol of each oligonucleotide primer per liter, and 
2.5 units of Tuq DNA polymerase (Perkin-Elmer/Cetus) in a 
total volume of 100 ~ 1 .  After denaturation at 94°C for 5 min, 
the reaction mixtures containing DNA were cycled 35 times for 
1 min at 94"C, 1 min at 56"C, and 1 min at 72°C. An extension 
of 2 min per cycle was included. A seminested PCR was 
performed on DNA from uncultured PBMC DNA, as de- 
scribed above. For the first PCR run, we used the outer primer 
1 
MTA-1 
K55 
p24 II, 
pl9 I.) 
rgp21 ~t 
r i t  
sets AGPl and WH2 (Table 1). Then, 2 ~1 was transferred to 
100 pl of the second PCR run, which included the inner primer 
sets AGP2 and WH2 (Table l), which amplified a fragment of 
1509 bp [nt 5133-6641 of the MO prototype (32)], including 55 
bases of thepol gene and the entire env gene (1462 bp). We also 
amplified 522 bp of the env/PX region (nt 6469-6991) using 
as the outer primer set WH1 and WH3 and as the inner set 
ETH403 and WH3 (Table 1). From the DNA of cultured cells 
(1 month) a 715-bp fragment of the LTR (nt 52-766) was also 
amplified using the primer set LTRII and 5PLTRE (Table 1). 
Cloning, Sequencing, and Phylogenetic Analysis. The DNAs 
amplified by the primer sets AGPl and WH2, ET403 and 
WH2, and LTRII and 5PLTR (which contains Not I and 
EcoRI restriction sites) were digested with Nor I and EcoRI 
restriction enzymes and cloned into a Bluescript vector and 
their nucleotide sequences were determined by the dide- 
oxynucleotide chain-termination method. Multiple alignment 
of the sequences was performed using the clustalv program 
(33) and analyzed with programs of the PHYLIFJ package 
version 3 .52~ (Josef Felsenstein, University of Washington, 
joegenetics.washington.edu) (34). 
RESULTS 
Eight of the 41 sera from the Bakola Pygmies had antibodies 
to HTLV-1/11 in the ELISA; two had optical densities of >1 
and <2 and six had optical densities of >3. In the confirmatory 
Western blot assay (Fig. l),  one had a typical HTLV-I pattern, 
with reactivity against p19, p24, rgp21, and MTA-1, and one 
had typical HTLV-II seroreactivity, against p24 >> p19, rgp21, 
FIG. 1. Western blot patterns 
of the sera of Bakola Pygmies from 
southwestern Cameroon, using the 
Western blot HTLV-1/11 2.3 from 
Diagnostic Biotechnology. Lanes: 
1, HTLV-I-positive control; 2, 
HTLV-II-positive control; 3, 
HTLV-I/II-negative control; 4, se- 
rum of the index case: HTLV-II- 
infected Pygmy woman, aged 59 
years; 5, serum of the HTLV-I- 
infected individual; 6-10, sera of 
five of the six Pygmies showing 
indeterminate Western blot pat- 
tern; 11, serum of an HTLV-I/& 
negative Pygmy. 
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and U5 .  The latter pattern was indistinguishable from that of 
the HTLV-II-positive controls, which included Tobas Amer- 
indians (35). Six further subjects. who had mainly gag-encoded 
proteins. were considered to be seroindeterminate (Fig. 1). 
The serum found to be HTLV-II-positive in the Western blot 
assay was that of a woman estimated to be 59 years old. who 
had never been transfused and had had no intimate contact 
with foreigners from Europe or the Americas. Higher HTLV 
antibody titers were found on C19 (1/12S0) than on MT2 
( 1/320) cells, confirming the presence of an HTLV-II infec- 
tion. 
After PBMCs from this woman were cultured for 2 weeks, 
a few reacted with both HTLV-I and HTLV-II polyclonal 
antisera and the patient’s serum. The number of fluorescent 
cells increased progressive!y, reaching 10-15$ after 40 days of 
culture and 30---10% after 5 months. Twenty-five to 30% of the 
cells were also faintly stained, after 5 months of culture, with 
the 7G5DS monoclonal antibody to HTLV-1/11 gp-16. but none 
was stained by the HTLV-I-specific p19 and $4 antibodies. 
When PBMCs were cocultivated with BJAB cells after 14 
days in culture, syncytia and giant cells (36.37) were seen after 
3 days: their numhers increased rapidly, leading to cell death. 
The syncytia were stained in the indirect immunofluorescence 
assay by both HTLV-I and HTLV-II polyclonal antisera. A 
high level of free p24 antigen was detectable in the supernatant 
of cell cultures after 2 weeks and remained so in further culture. 
After 5 months in culture. a few retroviral type C-like particles 
were detected in PBMCs under the electron microscope. The 
HTLV-II-infected cells were of T-cell lineage (95% CD2,94% 
and 1% CD20) with activation markers (94% HLA DR and 
70% CD25). 
A fragment consisting of 1509 bp (encompassing all of the 
em‘ gene) was amplified, cloned, and sequenced from the DNA 
of uncultured PBMCs by seminested PCR with the AGP2 and 
WH2 inner primer set. Comparison of this sequence with 
HTLV-II prototype strains demonstrated a very close homol- 
ogy with the subtype B group. Thus. in the total env gene (1461 
bp), HTLV-II PYGCAM-1 exhibited only 0.6% (9 substitu- 
tions) nucleotide divergence from G12 (15) and 0.75% (11 
substitutions) divergence from NRA (38) but exhibited 49 
divergence from the HTLV-II MO subtype A isolate (Fig. 2). 
Analysis of the 715-hp fragment of the LTR confirmed that 
PYGCAM-1 belongs to suhtype E, with a divergence of nine 
bases (1.3%) from the G E  prototype: two C deletions at 
position 135-146 (as compared with the MO isolate), five 
substitutions (T -+ C at 293, G -+ C at 312, G --f T at 313. A 
-+ G at 340, and C -+ T at 405). and two insertions (one A at 
117 and one G at 667); and a divergence of only four bases 
(0.6ri.) from the NRA prototype: one deletion of a C at 
position 145, one insertion of an A at 217 and two substitutions, 
a G - A  at 343 and an A -+ G at 651. 
A dendrogram comparing the nucleotide sequences of 559 
bp of the ern* gene (bp 60524640) showed that HTLV-II 
PYGCAM-1 was in the subtype B cluster (Fig. 3A), being 
closely related to GI2 isolate. Phylogenetic trees were con- 
CD3,26% CD4, S l %  CD5. 89% CD7, S7% CD8, 1% CD19. 
6031 
MO CTGCAACAACTCCATTATCCCCCCT~TCCCTC~TCCCGTACCTCCTCCGGCGAC~GACGCCGCCG~CCGTTCC 
G12 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
m .......................................c......................................... 
Pygcam . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .c. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
6112 
MO AATAGCAGTGTGGCTTGTCTCGCCCTAGCGGCCGGAACAGGTATCGCTGG~GAGTAACAGGC~CCTATCTCTGGCTTC 
MA ........................ T ........... ............................................. 
G12 ........................ T ........... ............................................. 
P y g C a m  ........................ T ........... ............................................. 
6193 
MO C A G T A P A 4 C C C T T C T C C T T T G A ~ G A ~ T ~ C C ~ C C T T A C C C A ~ C C A T A G T ~ T ~ T C A A A A C A T C C T  
NRA ................ T. ............... T ............................................... 
G12 ................ T ................ T. .............................................. 
PygCam ................ T.. .............. T.. ............................................. 
6274 
MO CCGGGTTGCACAGTATGCAGCCCAAAATAGACGAGGATTAGACCTCCTA~~~~C~G~~TT~TGCAAGGCCAT 
NRA ............ A ........... ......................................................... 
G12 ............ A ........... ......................................................... 
PygCam ............ A ........... ........................................................ 
6355 
MO ACAGGAGCMTGTTGCTTCCTCAACATCAGTAACACTCATGTATCCGTCCTCCA~~CGGCCCCCTCTTG~CGTGT 
NRA ........................ T ............................. A....................G..... 
G12 ........................ T. ....................................................... 
PygCam ........................ T ............................. A.. ........................ 
6436 
MO CATCACCGGCTGGGGACTAAACTGGGATCTTGGACTGTCCCAATGGGCACGAGMGCCCTCCAGACAGGCAT~CCATTCT 
NRA . . . . . . . . .  T ....................... ................................................ 
G12 
PygCam ......... T ....................... T..A.....G...................................... 
. . . . . . . . .  T.... ................... T..A.. . . .  G ...................................... 
6507 
MO CGCTCTAC“CCTCCTCGTCATA~TTTGGCCCCTGTAT~CTCCG~C~T~CA~CCCTTCCACAGCr~TTAC~CCG 
NRA .A.C. . . . . . . . . . .  T....................C.................A........G................. 
G12 ... C . . . . . . . . . . .  T. .C............. . . . . . . . . . . . . . . . . . .  G ................. 
.T .................... C . . . . . . . . . . . . .  G ................. 
6598 
MO A C A T k A C C A G T A T T C C C T T ; I T C M C C C C h ~ ~ ~ C C A T G C T A T ~ ~ ~ h ~ ~  r a  
.A . . .  
. . . . .  G ......................... 
..... G. . . .  C ............................ 
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FIG. 3. (A) Dendrogram comparing the nucleotide sequences of 
SS9 bp of the env region (bp 6052-6640) coding for the gp21. Two 
phylogenetic trees were obtained, one by the neighbor-joining method 
(34) (B) and one by maximum parsimony (data not shown). The den- 
drogram and the phylogenetic trees correspond to 16 different HTLV-II 
isolates including the PYGCAM-1 isolate generated in this study and 15 
other available published sequences comprising HTLV-II subtype A 
(MO) (32), subtype B [NRA (3S), G12 (IS)], and HTLV-II isolates 
representative of the different geographical origins: Amerindians (40SN, 
60405N, 130P, MSAlbp) (17), i.v. drug abusers from the USA (WH2, 
WH3, WH6, WH7) (36) or from Italy (GU, VA, BO, Md) (kindly 
communicated by U. Bertazonni). The HTLV-I ATK isolate was used as 
Outgroup to root the phylogenetic tree. 
structed by two different methods on the same env region coding 
for the gp21 (Fig. 3B) and on the LTR (data not shown). In 
both cases, the topology of the two trees was very simi- 
lar, demonstrating the existence of two molecular clusters of 
HTLV-II genotypes (with high bootstap values, 85-100%) 
with the PYGCAM-1 always included within the subtype B 
cluster. 
DISCUSSION 
Culture of PBMCs from a healthy 59-year-old Bakola Pygmy 
woman with HTLV-II serological markers resulted in the 
Proc. Natl. Acad Sci USA 92 (1995) 
establishment of a continuous CD8+ cell line containing an 
HTLV-II provirus that produces H"LV-II antigens and ret- 
roviral particles. Molecular analysis of this HTLV-II, PYG- 
CAM-1, demonstrated close homology with the HTLV-II 
subtype B prototypes (G12 and NRA) originally isolated from 
a Guaymi Amerindian in Panama (15) and from a United 
States patient with T hairy cell leukemia (38), respectively. We 
propose that this isolate, a genuine African HTLV-II, has been 
present in this remote population for a very long time, for the 
reasons outlined below. 
(i) Serum from the father of this woman as well as from three 
unrelated Bakola Pygmies living in the same area had shown 
similar seroreactivity (p24 >i P19, rgp21, and K55), indicating 
the presence of HTLV-II, 10 years previously (25). Isolation of 
an HTLV-II subtype B from the woman suggests that the four 
individuals were infected by the same virus. Furthermore, the 
presence of HTLV-II antibodies in the father of the index case 
supports the hypothesis that HTLV-II has been endemic in this 
population for at least two generations. Close contacts be- 
tween the Bakola Pygmy group and neighboring populations 
have been rare until recently. (¿i) A retrospective seroepide- 
miological survey of sera collected between 1967 and 1970 
from 214 Cameroonian Pygmies (24) showed HTLV-II-like 
seroreactivity in five. HTLV-II appears to be virtually absent 
in other ethnic groups in Cameroon (unpublished data). (iii) 
While most of the Pygmy groups tested were seronegative for 
HTLV-II antibodies, the only other African population de- 
scribed up to now in which HTLV-II is endemic is the Bambuti 
Pygmies in the Ituri region of northeast Zaire, where 14/102 
individuals in 1970 (24) and 4/12 in 1991 (22) were found to 
be HTLV-II-like seropositive. We failed to detect any HTLV- 
II-infected individuals in representative samples of Biaka 
Pygmies from the Lobaye region of the Central African 
Republic and of Twa Pygmies from the Lake Tomba area of 
Zaire (39). The Bambuti and Bakola Pygmies, both of which 
are infected with HTLV-II, are located at the western and 
eastern ends, respectively, of the present area of Pygmy 
habitation in central Africa and are of different paleoanthro- 
pological origins, with a divergence, based on linguistic and 
cultural features, of 10,000 years (27, 28). Taken together, 
these results strongly suggest that some isolated Pygmy pop- 
ulations have for a very long time been an African reservoù for 
HTLV-II infection. Since any close contact between these 
central African Pygmies and Amerindian populations is very 
unlikely to have occurred in the past, African HTLV-II may 
have diverged from a common ancestor long before HTLV-II 
was introduced into the Americas by perhaps two waves of 
migration over the Bering land bridge, each carrying one of the 
two molecular subtypes of HTLV-II (24) proposed by Hall et 
aL (16, 36, 37). Subtype A (prototype MO) is present mainly 
in US i.v. drug abusers (14, 36, 37) but also in the Pueblo 
Indians (17), whereas subtype B strains are found mainly in 
certain Amerindian groups scattered throughout North, Cen- 
tral, and South America, (refs. 12,14,16,40, and 41; M.B. and 
A.G., unpublished data). Subtype B is thus referred to as the 
Paleo-Indian strain. The nucleotidic divergence between the A 
and B subtypes is about 4.8% (15, 16, 37, 38). 
We were surprised to observe a genuine African HTLV-II 
so close genetically to the Paleo-Indian subtype B; however, 
genetic variability between strains of the same HTLV-II sub- 
type seems to be extremely low (16, 41). Thus, a nucleotide 
divergence of only O-0.4% (over 1000 bp of the e m  gene) was 
observed between HTLV-11s of different Amerindian groups 
who have probably had no contact for several thousand years 
(14-17, 41). The possibility that HTLV-II subtype B is a 
genuine African HTLV-II is reinforced by our recent finding 
of a subtype B variant in a Gabonese family (ref. 42; A.G., 
unpublished data). An HTLV-II B provirus has also been 
detected in two individuals in another area of Gabon and in 
Zaire (26). Only two other subtype A African isolates have 
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been described to date, one in Ghana (19) and the other in 
Cameroon (unpublished data), both in prostitutes, suggesting 
an imported infection. 
Preliminary data from Mongolia (43) showing the presence 
of a typical HTLV-II subtype A (16,32,36,37) strongly support 
the hypothesis that genetic drift is much lower for HTLV-II 
than for HTLV-I, for which, assuming a similar evolutionary 
rate for HTLV-1/11 in the different geographical locations, an 
estimated 0.5-1% nucleotide divergence (in the env and pol 
genes) during 1OOOyears of evolution has been proposed (8,11, 
In the context of recent evidence for interspecies transmis- 
sion in central and west Africa of PTLV-1 (HTLV-I/STLV-I) 
strains (46), we suggest that some STLV-II closely related to 
HTLV-II subtype B might exist or have existed in Africa. The 
recent finding of new PTLVs in several pygmy chimpanzees of 
Zairian origin [FWv'-PP1664 (6) and STLV-PP (7)] and in 
wild-caught baboons in Eritrea, Ethiopia (PTLV-L) (5), sup- 
ports the hypothesis of an African origin for some PTLVs (IO). 
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